Welcome to our dedicated page for P3 Health Partners news (Ticker: PIII), a resource for investors and traders seeking the latest updates and insights on P3 Health Partners stock.
P3 Health Partners Inc. (PIII) is a patient-centered, physician-led, and population health-focused healthcare company founded by Sherif Abdou and Amir Bacchus. The company is dedicated to transforming the way healthcare is delivered, with a mission to improve patient care, restore meaning to daily operations, and reinfuse care and health back into the healthcare system.
P3 operates with a unique model that aggregates and supports existing healthcare resources within the community to build an extensive network of providers. This network works collaboratively to deliver coordinated and integrated care to patients. The overarching goal is to improve patient outcomes, reduce healthcare costs, and enhance the overall experience for both patients and providers.
The team at P3 is composed of doctors, clinicians, and various support service professionals who share a deep passion for improving healthcare delivery. Recent achievements include significant growth in their provider network and successful partnerships that further their mission of delivering high-quality, cost-effective care.
Current projects at P3 include expanding their population health management services and implementing innovative care models that leverage data and technology to better serve their patient populations. Financially, P3 Health Partners Inc. continues to show robust performance, supported by its strong operational framework and strategic partnerships.
The company remains committed to its vision of transforming healthcare by working closely with physicians and healthcare providers to bring about meaningful changes in patient care delivery.
P3 Health Partners Inc. (NASDAQ: PIII) reported its Q4 and full-year 2022 financial results, with a notable 40% increase in capitated revenue to $254.0 million. However, the company faced a substantial net loss of $532.3 million, primarily due to a goodwill impairment charge of $463.5 million. For the full year, P3's at-risk Medicare Advantage membership grew by 50% to 100,400, with total revenues reaching $1.0 billion, a 66% increase from the previous year. Looking forward, P3 anticipates achieving Adjusted EBITDA positivity by early 2024 and has provided fiscal 2023 guidance with total revenues projected between $1.2 billion and $1.25 billion.
P3 Health Partners Inc. (NASDAQ: PIII) announced a definitive agreement for a private placement of securities, expected to yield approximately
P3 Health Partners Inc. (NASDAQ: PIII) announced it will release its fourth-quarter 2022 and full-year 2022 results on March 31, 2023, before the market opens. Management will host a conference call and webcast at 8:30 AM ET on the same day to discuss corporate and financial updates. P3 is a physician-led population health management company with over 2,800 affiliated primary care providers across five states. The call details will be provided on the company’s investor page, and an archived recording will be available for 90 days post-event.
P3 Health Partners Inc. (NASDAQ: PIII) plans to release its financial results for the fourth quarter and full year ending December 31, 2022, on March 30, 2023. The company will also file its Annual Report on Form 10-K on the same day. An investor call and webcast are scheduled for 4:30 PM ET to discuss the financial performance and provide a corporate update. P3 Health Partners focuses on improving healthcare through a network of over 2,800 affiliated primary care providers across five states. Further details will be available on their investor relations page.
P3 Health Partners Inc. (NASDAQ: PIII) announced its intention to file the Annual Report on Form 10-K by March 30, 2023. The delay is attributed to an administrative issue related to the delayed audit for 2021. P3 reaffirmed its 2022 revenue guidance of $1.025 billion to $1.075 billion, representing a 61% to 69% increase year-over-year. They expect at-risk Medicare Advantage membership to exceed 100,000, a 35% rise from 2021. The 2023 guidance includes revenue expectations of $1.20 billion to $1.25 billion and an Adjusted EBITDA loss of $40 million to $60 million. P3 anticipates achieving Adjusted EBITDA profitability by 2024.
FAQ
What is the current stock price of P3 Health Partners (PIII)?
What is the market cap of P3 Health Partners (PIII)?
What is P3 Health Partners Inc.?
Who founded P3 Health Partners?
What is the main mission of P3 Health Partners?
How does P3 Health Partners operate?
What recent achievements has P3 Health Partners made?
What current projects is P3 Health Partners involved in?
How does P3 Health Partners aim to improve patient outcomes?
What makes P3 Health Partners unique?
How can I stay updated on P3 Health Partners' news?
What is the financial condition of P3 Health Partners?
